MedPage Today  |  May 9, 2023

“The Orphan Drug Act comes from a good place, which is [to get companies]
to invest in these rare diseases, since they’re not going to make a lot of
money because the population is very small,” co-author Sean Tu, JD, PhD, of
West Virginia University in Morgantown, told MedPage Today. “But we show
that’s not true. They’re making a ton of money.”

Read more here.